INBX
Inhibrx Biosciences Inc.
$89.83
-0.67
(-0.74%)
Mkt Cap
1.32B
Volume
145,923
52W Range
28.16-155.29
Sector
Healthcare
Beta
3.82
EPS (TTM)
-8.88 USD
P/E Ratio
-8.74
Revenue (TTM)
0 USD
Rev Growth (5Y)
-36.7%
EPS Growth (5Y)
N/A
Company Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30M | 200,000 | 1.80M | 2.19M | 7.12M | 12.81M | 9.09M | 8.60M | 8.39M | 6.67M |
| Net Income | (140.06M) | 1.69B | (241.36M) | (145.23M) | (81.77M) | (75.64M) | (51.40M) | (31.16M) | (19.44M) | (8.27M) |
| EPS | -9.04 | 116.58 | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 | -0.68 | -0.23 |
| Free Cash Flow | (129.82M) | (197.01M) | (197.90M) | (115.99M) | (81.19M) | (49.33M) | (33.89M) | (24.52M) | (20.09M) | (18.32M) |
| FCF / Share | -8.38 | -13.61 | -4.20 | -2.89 | -2.14 | -1.95 | -0.93 | -0.91 | -0.70 | -0.50 |
| Operating CF | (129.79M) | (194.41M) | (193.31M) | (115.30M) | (80.32M) | (47.97M) | (32.08M) | (23.09M) | (18.75M) | (18.11M) |
| Total Assets | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M | 143.74M | 26.49M | 9.98M | 17.25M | 21.27M |
| Total Debt | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M | 37.45M | 41.73M | 9.49M | 14.66M | 18.92M |
| Cash & Equiv | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M | 128.66M | 11.54M | 2.10M | 13.47M | 20.02M |
| Book Value | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M | 75.47M | (93.57M) | (57.64M) | (28.77M) | (9.25M) |
| Return on Equity | -17.52 | 12.63 | -5.55 | -2.50 | -1.56 | -1.00 | N/A | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.30M | 0 | 100,000 | 0 | 100,000 | 0 | 1.63M | 119,000 |
| Net Income | (36.65M) | (33.44M) | (32.83M) | (35.26M) | (28.65M) | (43.31M) | (47.87M) | (43.86M) | 1.86B | (78.71M) | (93.60M) | (51.79M) |
| EPS | -2.34 | -2.15 | -2.11 | -2.28 | -1.85 | -2.80 | -3.31 | -2.84 | 127.10 | -1.44 | -1.73 | -1.10 |
| Free Cash Flow | (29.89M) | (38.03M) | (30.12M) | (33.83M) | (29.95M) | (35.92M) | (43.74M) | (30.53M) | (58.57M) | (64.17M) | (60.26M) | (55.06M) |
| FCF / Share | -1.91 | -2.44 | -1.94 | -2.19 | -1.94 | -2.32 | -3.02 | -1.97 | -4.01 | -1.18 | -1.12 | -1.17 |
| Operating CF | (29.92M) | (38.03M) | (30.12M) | (33.82M) | (29.95M) | (35.90M) | (43.72M) | (30.28M) | (57.36M) | (63.05M) | (56.82M) | (54.24M) |
| Total Assets | 154.22M | 183.97M | 146.48M | 177.47M | 212.12M | 242.64M | 180.77M | 222.56M | 258.42M | 288.58M | 307.89M | 372.73M |
| Total Debt | 5.34M | 5.90M | 107.01M | 6.99M | 106.79M | 106.53M | 8.05M | 1.83M | 2.17M | 210.89M | 210.14M | 207.37M |
| Cash & Equiv | 133.34M | 161.66M | 124.22M | 153.09M | 186.57M | 216.52M | 152.60M | 196.33M | 226.86M | 252.48M | 277.92M | 337.33M |
| Book Value | (52.98M) | (21.04M) | 7.99M | 36.83M | 68.56M | 94.44M | 133.58M | 178.47M | 219.37M | 11.57M | 43.50M | 129.59M |
| Return on Equity | N/A | N/A | -4.11 | -0.96 | -0.42 | -0.46 | -0.36 | -0.25 | 8.47 | -6.80 | -2.15 | -0.40 |
INBX News
Inhibrx Announces Participation in Upcoming Scientific Conferences
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activity
Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 Shares
Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Purchases $500,000.00 in Stock
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom